23andMe announces publication of genome-wide association study of motion sickness 23andMe.

Movement sickness has been shown to possess high heritability, signifying genetics accounts for a large component of why some are even more prone to movement sickness than others. Estimates show that up to 70 % of variation in risk for motion sickness is due to genetics. ‘Until now there's been a poor understanding of the genetics of motion sickness, despite it being truly a common condition pretty,’ said 23andMe Scientist Bethann Hromatka, lead writer of the study. ‘With the help of 23andMe clients we've had the opportunity to uncover a few of the underlying genetics of this condition. These findings may help provide clues about the causes of motion sickness and additional related conditions, and how to treat them, which is quite interesting.’ Related StoriesNew ACMG Scope of Practice of the Specialty of Medical Genetics record releasedGenetics and race influence sufferers' response to anticancer drug treatmentsAmbry Genetics presents groundbreaking TP53 gene data at ASHG; TP53 associated with breast cancerThe research, which involved the consented participation of more than 80,000 23andMe customers, found 35 genetic factors associated with motion sickness at a genome-wide significant level.Bojesen, M.D., Ph.D., D.M.Sc.: Statin Use and Reduced Cancer-Related Mortality Cholesterol is a simple structural element of mammalian cell membranes and is vital for cellular proliferation.1,2 Statins inhibit the creation of endogenous block and cholesterol3 protein prenylation, and statin use may therefore influence cell proliferation and migration.4,5 Cancer-cell proliferation sometimes appears clinically as cancer development and metastasis, and it ultimately results in the loss of life of the patient. A decrease in the option of cholesterol may lead to decreased proliferation and migration of cancer cells.6,7 Also, a reduction in the downstream items in the mevalonate pathway because of statin use has been connected with several potential anticancer properties8-12 and a reduced risk of cancer recurrence.13,14 At the cellular level, statins have already been linked to the halting of cell-routine progression and to increased radiosensitization in malignancy cells.10,15,16 Thus, regular statin use before and after a analysis of cancer could theoretically reduce cancer-related mortality.